Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company's Portfolio

Annovis Bio -8.59% Post

Annovis Bio

ANVS

11.39

11.20

-8.59%

-1.67% Post

Annovis Bio, Inc. (NYSE:ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, announced the filing of a patent application covering the use of buntanetap and its analogues for the treatment of neuropsychiatric indications. This application follows the U.S. Provisional Application No. 63/440,890 which was filed on January 24, 2023.

Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via